Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| QuidelOrtho CorpQDEL · Entity 4986 | Director · President & CEO | February 08, 2024 | February 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
QuidelOrtho Corp
Report date February 08, 2024 · Filed February 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 46,254 |
Reported balance
After 2024-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-08 · Grant · Acquired 46,254 · Balance 46,254 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: 46,254 shares will vest in equal installments on February 8, 2025, February 8, 2026 and February 8, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
F2: 46,254 shares will vest in equal installments on February 8, 2025, February 8, 2026 and February 8, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
QUIDEL CORP /DE/
Report date May 27, 2022 · Filed June 01, 2022
Section 16 reporting ended · disclosed 2022-06-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 1
1 source rowRow 1 · 2022-05-27 · Disposition to issuer · Disposed 505,926 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $15.40 · Expires 2026-02-10 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-27 · Disposition to issuer · Disposed 23,461 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $21.08 · Expires 2027-02-15 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-27 · Disposition to issuer · Disposed 20,249 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $46.41 · Expires 2028-01-16 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-27 · Disposition to issuer · Disposed 27,637 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $59.12 · Expires 2029-02-04 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-27 · Disposition to issuer · Disposed 37,440 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: 28,080 shares are vested in full; 9,360 shares will vest on February 4, 2023. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $77.16 · Expires 2030-02-03 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-27 · Disposition to issuer · Disposed 30,358 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F5: 15,180 shares are vested in full; the remaining 15,178 shares will vest in equal installments on February 3, 2023 and February 3, 2024. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $228.21 · Expires 2030-08-24 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-27 · Disposition to issuer · Disposed 10,593 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: 3,531 shares are vested in full; the remaining 7,062 shares will vest in equal installments on August 24, 2022 and August 24, 2023. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $254.00 · Expires 2031-02-01 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-05-27 · Disposition to issuer · Disposed 8,924 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F7: 2,231 shares are vested in full; the remaining 6,693 shares will vest in equal installments on February 1, 2023, February 1, 2024 and February 1, 2025. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $142.45 · Expires 2031-07-28 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-05-27 · Disposition to issuer · Disposed 11,140 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: 3,713 shares will vest on July 28, 2022; 3,713 shares will vest on July 28, 2023; and 3,714 shares will vest on July 28, 2024. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $103.36 · Expires 2032-01-31 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-05-27 · Disposition to issuer · Disposed 27,043 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F9: 6,760 shares will vest on January 31, 2023; the remaining 20,283 shares will vest in equal installments on January 31, 2024, January 31, 2025 and January 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-05-27 · Disposition to issuer · Disposed 18,720 · Balance 0 F10: Each restricted stock unit represents the right to receive one share of Quidel common stock. F11: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F12: 18,720 shares will vest on February 4, 2023. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-05-27 · Disposition to issuer · Disposed 7,309 · Balance 0 F10: Each restricted stock unit represents the right to receive one share of Quidel common stock. F11: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F13: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2022-05-27 · Disposition to issuer · Disposed 2,192 · Balance 0 F10: Each restricted stock unit represents the right to receive one share of Quidel common stock. F11: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F13: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2022-05-27 · Disposition to issuer · Disposed 7,590 · Balance 0 F10: Each restricted stock unit represents the right to receive one share of Quidel common stock. F11: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F14: 7,590 shares will vest in equal installments on February 3, 2023 and February 3, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2022-05-27 · Disposition to issuer · Disposed 2,921 · Balance 0 F10: Each restricted stock unit represents the right to receive one share of Quidel common stock. F11: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F15: 1,460 shares will vest on August 24, 2022 and 1,461 shares will vest on August 24, 2023. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2022-05-27 · Disposition to issuer · Disposed 3,347 · Balance 0 F10: Each restricted stock unit represents the right to receive one share of Quidel common stock. F11: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F16: 1,115 shares will vest on February 1, 2023; the remaining 2,232 shares will vest in equal installments on February 1, 2024 and February 1, 2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2022-05-27 · Disposition to issuer · Disposed 27,043 · Balance 0 F10: Each restricted stock unit represents the right to receive one share of Quidel common stock. F11: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F17: 6,760 shares will vest on January 31, 2023; the remaining 20,283 shares will vest in equal installments on January 31, 2024, January 31, 2025 and January 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2022-05-27 · Disposition to issuer · Disposed 24,187 · Balance 0 F10: Each restricted stock unit represents the right to receive one share of Quidel common stock. F11: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F18: 12,093 shares will vest on January 31, 2024; the remaining 12,094 shares will vest in equal installments on January 31, 2025 and January 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2022-05-27 · Disposition to issuer · Disposed 2,646 · Balance 0 F10: Each restricted stock unit represents the right to receive one share of Quidel common stock. F11: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F13: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2022-05-27 · Disposition to issuer · Disposed 794 · Balance 0 F10: Each restricted stock unit represents the right to receive one share of Quidel common stock. F11: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F13: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. F19: 794 shares will vest on January 31, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F3: Vested in full.
F4: 28,080 shares are vested in full; 9,360 shares will vest on February 4, 2023.
F5: 15,180 shares are vested in full; the remaining 15,178 shares will vest in equal installments on February 3, 2023 and February 3, 2024.
F6: 3,531 shares are vested in full; the remaining 7,062 shares will vest in equal installments on August 24, 2022 and August 24, 2023.
F7: 2,231 shares are vested in full; the remaining 6,693 shares will vest in equal installments on February 1, 2023, February 1, 2024 and February 1, 2025.
F8: 3,713 shares will vest on July 28, 2022; 3,713 shares will vest on July 28, 2023; and 3,714 shares will vest on July 28, 2024.
F9: 6,760 shares will vest on January 31, 2023; the remaining 20,283 shares will vest in equal installments on January 31, 2024, January 31, 2025 and January 31, 2026.
F10: Each restricted stock unit represents the right to receive one share of Quidel common stock.
F11: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F12: 18,720 shares will vest on February 4, 2023.
F13: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule.
F14: 7,590 shares will vest in equal installments on February 3, 2023 and February 3, 2024.
F15: 1,460 shares will vest on August 24, 2022 and 1,461 shares will vest on August 24, 2023.
F16: 1,115 shares will vest on February 1, 2023; the remaining 2,232 shares will vest in equal installments on February 1, 2024 and February 1, 2025.
F17: 6,760 shares will vest on January 31, 2023; the remaining 20,283 shares will vest in equal installments on January 31, 2024, January 31, 2025 and January 31, 2026.
F18: 12,093 shares will vest on January 31, 2024; the remaining 12,094 shares will vest in equal installments on January 31, 2025 and January 31, 2026.
F19: 794 shares will vest on January 31, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2022 Filed Jun 1, 2022 16:18 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerRestricted Stock Units · Derivative | 2,921 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020387 · doc4.xml · derivative · entry 15 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,921 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F11 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F15 · derivative.exercise_date: 1,460 shares will vest on August 24, 2022 and 1,461 shares will vest on August 24, 2023. F15 · derivative.expiration_date: 1,460 shares will vest on August 24, 2022 and 1,461 shares will vest on August 24, 2023. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:18 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerRestricted Stock Units · Derivative | 7,590 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020387 · doc4.xml · derivative · entry 14 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,590 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F11 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F14 · derivative.exercise_date: 7,590 shares will vest in equal installments on February 3, 2023 and February 3, 2024. F14 · derivative.expiration_date: 7,590 shares will vest in equal installments on February 3, 2023 and February 3, 2024. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:18 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerRestricted Stock Units · Derivative | 2,192 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020387 · doc4.xml · derivative · entry 13 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,192 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F11 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F13 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. F13 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:18 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerRestricted Stock Units · Derivative | 7,309 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020387 · doc4.xml · derivative · entry 12 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,309 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F11 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F13 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. F13 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:18 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerRestricted Stock Units · Derivative | 18,720 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020387 · doc4.xml · derivative · entry 11 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,720 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel common stock. F11 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F12 · derivative.exercise_date: 18,720 shares will vest on February 4, 2023. F12 · derivative.expiration_date: 18,720 shares will vest on February 4, 2023. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:18 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerNon-Qualified Stock Options · Derivative | 27,043 | $0.00 Strike: $103.36 | $0.00 |
DisclosureSEC source: 0000899243-22-020387 · doc4.xml · derivative · entry 10 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,043 shares Expires 2032-01-31 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F9 · derivative.exercise_date: 6,760 shares will vest on January 31, 2023; the remaining 20,283 shares will vest in equal installments on January 31, 2024, January 31, 2025 and January 31, 2026. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:18 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerNon-Qualified Stock Options · Derivative | 11,140 | $0.00 Strike: $142.45 | $0.00 |
DisclosureSEC source: 0000899243-22-020387 · doc4.xml · derivative · entry 9 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,140 shares Expires 2031-07-28 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8 · derivative.exercise_date: 3,713 shares will vest on July 28, 2022; 3,713 shares will vest on July 28, 2023; and 3,714 shares will vest on July 28, 2024. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:18 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerNon-Qualified Stock Options · Derivative | 8,924 | $0.00 Strike: $254.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020387 · doc4.xml · derivative · entry 8 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,924 shares Expires 2031-02-01 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F7 · derivative.exercise_date: 2,231 shares are vested in full; the remaining 6,693 shares will vest in equal installments on February 1, 2023, February 1, 2024 and February 1, 2025. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:18 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerNon-Qualified Stock Options · Derivative | 10,593 | $0.00 Strike: $228.21 | $0.00 |
DisclosureSEC source: 0000899243-22-020387 · doc4.xml · derivative · entry 7 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,593 shares Expires 2030-08-24 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6 · derivative.exercise_date: 3,531 shares are vested in full; the remaining 7,062 shares will vest in equal installments on August 24, 2022 and August 24, 2023. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:18 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerNon-Qualified Stock Options · Derivative | 30,358 | $0.00 Strike: $77.16 | $0.00 |
DisclosureSEC source: 0000899243-22-020387 · doc4.xml · derivative · entry 6 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,358 shares Expires 2030-02-03 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F5 · derivative.exercise_date: 15,180 shares are vested in full; the remaining 15,178 shares will vest in equal installments on February 3, 2023 and February 3, 2024. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:18 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerNon-Qualified Stock Options · Derivative | 37,440 | $0.00 Strike: $59.12 | $0.00 |
DisclosureSEC source: 0000899243-22-020387 · doc4.xml · derivative · entry 5 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,440 shares Expires 2029-02-04 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4 · derivative.exercise_date: 28,080 shares are vested in full; 9,360 shares will vest on February 4, 2023. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:18 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerNon-Qualified Stock Options · Derivative | 27,637 | $0.00 Strike: $46.41 | $0.00 |
DisclosureSEC source: 0000899243-22-020387 · doc4.xml · derivative · entry 4 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,637 shares Expires 2028-01-16 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:18 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerNon-Qualified Stock Options · Derivative | 20,249 | $0.00 Strike: $21.08 | $0.00 |
DisclosureSEC source: 0000899243-22-020387 · doc4.xml · derivative · entry 3 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,249 shares Expires 2027-02-15 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:18 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerNon-Qualified Stock Options · Derivative | 23,461 | $0.00 Strike: $15.40 | $0.00 |
DisclosureSEC source: 0000899243-22-020387 · doc4.xml · derivative · entry 2 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,461 shares Expires 2026-02-10 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:18 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Disposition to issuerCommon Stock | 505,926 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-020387 · doc4.xml · nonDerivative · entry 1 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. F1 · price: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 794 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 20 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 794 Underlying: Common Stock · 794 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F11 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F13 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. F19 · derivative.exercise_date: 794 shares will vest on January 31, 2023. F13 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. F19 · derivative.expiration_date: 794 shares will vest on January 31, 2023. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 2,646 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 19 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,646 Underlying: Common Stock · 2,646 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F11 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F13 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. F13 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 24,187 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 18 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,187 Underlying: Common Stock · 24,187 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F11 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F18 · derivative.exercise_date: 12,093 shares will vest on January 31, 2024; the remaining 12,094 shares will vest in equal installments on January 31, 2025 and January 31, 2026. F18 · derivative.expiration_date: 12,093 shares will vest on January 31, 2024; the remaining 12,094 shares will vest in equal installments on January 31, 2025 and January 31, 2026. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 27,043 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 17 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,043 Underlying: Common Stock · 27,043 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F11 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F17 · derivative.exercise_date: 6,760 shares will vest on January 31, 2023; the remaining 20,283 shares will vest in equal installments on January 31, 2024, January 31, 2025 and January 31, 2026. F17 · derivative.expiration_date: 6,760 shares will vest on January 31, 2023; the remaining 20,283 shares will vest in equal installments on January 31, 2024, January 31, 2025 and January 31, 2026. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 3,347 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 16 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,347 Underlying: Common Stock · 3,347 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F11 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F16 · derivative.exercise_date: 1,115 shares will vest on February 1, 2023; the remaining 2,232 shares will vest in equal installments on February 1, 2024 and February 1, 2025. F16 · derivative.expiration_date: 1,115 shares will vest on February 1, 2023; the remaining 2,232 shares will vest in equal installments on February 1, 2024 and February 1, 2025. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 2,921 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 15 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,921 Underlying: Common Stock · 2,921 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F11 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F15 · derivative.exercise_date: 1,460 shares will vest on August 24, 2022 and 1,461 shares will vest on August 24, 2023. F15 · derivative.expiration_date: 1,460 shares will vest on August 24, 2022 and 1,461 shares will vest on August 24, 2023. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 7,590 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 14 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,590 Underlying: Common Stock · 7,590 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F11 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F14 · derivative.exercise_date: 7,590 shares will vest in equal installments on February 3, 2023 and February 3, 2024. F14 · derivative.expiration_date: 7,590 shares will vest in equal installments on February 3, 2023 and February 3, 2024. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 2,192 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 13 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,192 Underlying: Common Stock · 2,192 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F11 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F13 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. F13 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 7,309 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 12 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,309 Underlying: Common Stock · 7,309 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F11 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F13 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. F13 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and will occur according to the elected deferral schedule. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 18,720 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 11 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,720 Underlying: Common Stock · 18,720 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F11 · kind: Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F12 · derivative.exercise_date: 18,720 shares will vest on February 4, 2023. F12 · derivative.expiration_date: 18,720 shares will vest on February 4, 2023. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Options · Derivative | 27,043 | $0.00 Strike: $103.36 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 10 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,043 Underlying: Common Stock · 27,043 shares Expires 2032-01-31 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options were converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F9 · derivative.exercise_date: 6,760 shares will vest on January 31, 2023; the remaining 20,283 shares will vest in equal installments on January 31, 2024, January 31, 2025 and January 31, 2026. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Options · Derivative | 11,140 | $0.00 Strike: $142.45 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 9 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,140 Underlying: Common Stock · 11,140 shares Expires 2031-07-28 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options were converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8 · derivative.exercise_date: 3,713 shares will vest on July 28, 2022; 3,713 shares will vest on July 28, 2023; and 3,714 shares will vest on July 28, 2024. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Options · Derivative | 8,924 | $0.00 Strike: $254.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 8 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,924 Underlying: Common Stock · 8,924 shares Expires 2031-02-01 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options were converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F7 · derivative.exercise_date: 2,231 shares are vested in full; the remaining 6,693 shares will vest in equal installments on February 1, 2023, February 1, 2024 and February 1, 2025. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Options · Derivative | 10,593 | $0.00 Strike: $228.21 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 7 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,593 Underlying: Common Stock · 10,593 shares Expires 2030-08-24 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options were converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6 · derivative.exercise_date: 3,531 shares are vested in full; the remaining 7,062 shares will vest in equal installments on August 24, 2022 and August 24, 2023. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Options · Derivative | 30,358 | $0.00 Strike: $77.16 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 6 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,358 Underlying: Common Stock · 30,358 shares Expires 2030-02-03 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options were converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F5 · derivative.exercise_date: 15,180 shares are vested in full; the remaining 15,178 shares will vest in equal installments on February 3, 2023 and February 3, 2024. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Options · Derivative | 37,440 | $0.00 Strike: $59.12 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 5 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,440 Underlying: Common Stock · 37,440 shares Expires 2029-02-04 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options were converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4 · derivative.exercise_date: 28,080 shares are vested in full; 9,360 shares will vest on February 4, 2023. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Options · Derivative | 27,637 | $0.00 Strike: $46.41 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 4 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,637 Underlying: Common Stock · 27,637 shares Expires 2028-01-16 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options were converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Options · Derivative | 20,249 | $0.00 Strike: $21.08 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 3 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,249 Underlying: Common Stock · 20,249 shares Expires 2027-02-15 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options were converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Options · Derivative | 23,461 | $0.00 Strike: $15.40 | $0.00 |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · derivative · entry 2 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,461 Underlying: Common Stock · 23,461 shares Expires 2026-02-10 F2 · kind: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options were converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3 · derivative.exercise_date: Vested in full. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 505,926 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-020508 · doc4.xml · nonDerivative · entry 1 BRYANT DOUGLAS C · CIK 0001406652 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,926 F1 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. F1 · price: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 19:54 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionRestricted Stock Units · Derivative | 3,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007618 · doc4.xml · derivative · entry 3 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,590 Underlying: Common Stock · 3,795 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one (1) share of Quidel Corporation common stock. F4 · derivative.exercise_date: One-quarter of the shares subject to the original grant vest annually over a four-year period, commencing on the first anniversary date of the grant date. F4 · derivative.expiration_date: One-quarter of the shares subject to the original grant vest annually over a four-year period, commencing on the first anniversary date of the grant date. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 19:54 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Tax withholdingCommon Stock | 1,882 | $99.68 | $187,597.76 |
DisclosureSEC source: 0001209191-22-007618 · doc4.xml · nonDerivative · entry 2 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,926 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 19:54 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantCommon Stock | 3,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007618 · doc4.xml · nonDerivative · entry 1 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507,808 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 19:53 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionRestricted Stock Units · Derivative | 3,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007617 · doc4.xml · derivative · entry 3 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,590 Underlying: Common Stock · 3,795 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one (1) share of Quidel Corporation common stock. F4 · derivative.exercise_date: One-quarter of the shares subject to the original grant vest annually over a four-year period, commencing on the first anniversary date of the grant date. F4 · derivative.expiration_date: One-quarter of the shares subject to the original grant vest annually over a four-year period, commencing on the first anniversary date of the grant date. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 19:53 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Tax withholdingCommon Stock | 1,882 | $99.68 | $187,597.76 |
DisclosureSEC source: 0001209191-22-007617 · doc4.xml · nonDerivative · entry 2 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,926 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 19:53 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantCommon Stock | 3,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007617 · doc4.xml · nonDerivative · entry 1 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507,808 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:55 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionRestricted Stock Units · Derivative | 1,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006631 · doc4.xml · derivative · entry 8 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,347 Underlying: Common Stock · 1,115 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one (1) share of Quidel Corporation common stock. F9 · derivative.exercise_date: One-quarter of the shares subject to the original grant vest annually over a four-year period, commencing on the first anniversary date of the grant date. F9 · derivative.expiration_date: One-quarter of the shares subject to the original grant vest annually over a four-year period, commencing on the first anniversary date of the grant date. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:55 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Tax withholdingCommon Stock | 553 | $102.32 | $56,582.96 |
DisclosureSEC source: 0001209191-22-006631 · doc4.xml · nonDerivative · entry 2 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,013 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:55 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantCommon Stock | 1,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006631 · doc4.xml · nonDerivative · entry 1 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,566 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:55 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Premium) · Derivative | 794 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006631 · doc4.xml · derivative · entry 7 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 794 Underlying: Common Stock · 794 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one (1) share of Quidel Corporation common stock. F6 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person under a deferred compensation program applicable to participating employees. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F8 · derivative.exercise_date: The restricted stock units vest on January 31, 2023. F6 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person under a deferred compensation program applicable to participating employees. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F8 · derivative.expiration_date: The restricted stock units vest on January 31, 2023. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:55 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Converted) · Derivative | 2,646 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006631 · doc4.xml · derivative · entry 6 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,646 Underlying: Common Stock · 2,646 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one (1) share of Quidel Corporation common stock. F6 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person under a deferred compensation program applicable to participating employees. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F7 · derivative.exercise_date: The restricted stock units vest on January 31, 2022. F6 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person under a deferred compensation program applicable to participating employees. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F7 · derivative.expiration_date: The restricted stock units vest on January 31, 2022. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:55 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units · Derivative | 24,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006631 · doc4.xml · derivative · entry 5 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,187 Underlying: Common Stock · 24,187 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one (1) share of Quidel Corporation common stock. F5 · derivative.exercise_date: 12,093 shares vest on the second anniversary date of the grant date, January 31, 2024; 6,047 shares vest on the third anniversary date of the grant date, January 31, 2025; and 6,047 shares vest on the fourth anniversary date of the grant date, January 31, 2026. F5 · derivative.expiration_date: 12,093 shares vest on the second anniversary date of the grant date, January 31, 2024; 6,047 shares vest on the third anniversary date of the grant date, January 31, 2025; and 6,047 shares vest on the fourth anniversary date of the grant date, January 31, 2026. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:55 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units · Derivative | 27,043 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006631 · doc4.xml · derivative · entry 4 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,043 Underlying: Common Stock · 27,043 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one (1) share of Quidel Corporation common stock. F3 · derivative.exercise_date: 6,760 shares vest on the first anniversary date of the grant date, January 31, 2023; 6,761 shares vest on the second anniversary date of the grant date, January 31, 2024; 6,761 shares vest on the third anniversary date of the grant date, January 31, 2025; and 6,761 shares vest on the fourth anniversary date of the grant date, January 31, 2026. F3 · derivative.expiration_date: 6,760 shares vest on the first anniversary date of the grant date, January 31, 2023; 6,761 shares vest on the second anniversary date of the grant date, January 31, 2024; 6,761 shares vest on the third anniversary date of the grant date, January 31, 2025; and 6,761 shares vest on the fourth anniversary date of the grant date, January 31, 2026. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:55 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantNon-Qualified Stock Option · Derivative | 27,043 | $0.00 Strike: $103.36 | $0.00 |
DisclosureSEC source: 0001209191-22-006631 · doc4.xml · derivative · entry 3 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,043 Underlying: Common Stock · 27,043 shares Expires 2032-01-31 F3 · derivative.exercise_date: 6,760 shares vest on the first anniversary date of the grant date, January 31, 2023; 6,761 shares vest on the second anniversary date of the grant date, January 31, 2024; 6,761 shares vest on the third anniversary date of the grant date, January 31, 2025; and 6,761 shares vest on the fourth anniversary date of the grant date, January 31, 2026. Read SEC document |
| January 16, 2022 Filed Jan 19, 2022 20:00 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionRestricted Stock Units · Derivative | 13,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003870 · doc4.xml · derivative · entry 3 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,819 shares Expires 2022-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one (1) share of Quidel Corporation common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.